Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Corcept Therapeutics Incorporated's Expenses

Biotech Giants' Cost Evolution: Regeneron vs. Corcept

__timestampCorcept Therapeutics IncorporatedRegeneron Pharmaceuticals, Inc.
Wednesday, January 1, 2014882000205018000
Thursday, January 1, 20151361000392709000
Friday, January 1, 20162058000299694000
Sunday, January 1, 20173554000397061000
Monday, January 1, 20185215000434100000
Tuesday, January 1, 20195504000782200000
Wednesday, January 1, 202055820001119900000
Friday, January 1, 202152810002437500000
Saturday, January 1, 202253850001560400000
Sunday, January 1, 202364810001815800000
Monday, January 1, 20241970500000
Loading chart...

In pursuit of knowledge

Cost Insights: A Financial Journey of Two Biotech Giants

In the competitive world of biotechnology, understanding cost structures is crucial. Regeneron Pharmaceuticals, Inc. and Corcept Therapeutics Incorporated, two prominent players, have shown distinct financial trajectories over the past decade. From 2014 to 2023, Regeneron's cost of revenue surged by approximately 785%, reflecting its aggressive expansion and increased production capabilities. In contrast, Corcept's cost of revenue grew by about 635%, indicating a steady yet significant rise in operational expenses.

A Decade of Growth and Challenges

Regeneron's peak in 2021, with costs reaching nearly $2.44 billion, underscores its rapid scaling and market penetration. Meanwhile, Corcept's consistent growth, culminating in a 2023 cost of $6.48 million, highlights its strategic focus on niche markets. These trends not only reveal the companies' financial strategies but also provide insights into the broader biotech industry's evolution.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025